Description
Lu-dfc413 is an experimental medicine being studied by Novartis Pharmaceuticals. It is a type of targeted therapy that uses a radioactive substance (Lutetium-177) attached to a molecule designed to find and bind to specific targets on cancer cells. It is being tested in patients with solid tumors, including colorectal cancer, particularly those with certain characteristics like HER2 mutations or MSI-H status. The goal of the clinical trials is to determine the safe dose and see if Lu-dfc413 can shrink tumors or slow their growth. It is currently in Phase 1 trials, meaning it is being tested for the first time in humans to assess safety and determine the best way to give it.
Mechanism of Action
Lu-dfc413 is a targeted radiopharmaceutical. It combines Lutetium-177, a radioactive isotope, with a targeting molecule (likely related to Ga-NNS309, which is used for imaging). The targeting molecule is designed to bind specifically to certain proteins or markers found on the surface of cancer cells. Once attached, the radioactive Lutetium-177 emits radiation that damages the cancer cells, potentially leading to their death. The specific molecular target is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.